Advanced in X-Linked Agammaglobulinemia

Clementien L. Vermont

Rotterdam, ZH, NL 
Advanced in X-Linked Agammaglobulinemia
Rotterdam, ZH, NL 
OverviewLocationsClinical Research

Overview

Clementien Vermont practices in Rotterdam, Netherlands. Vermont is rated as an Advanced expert by MediFind in the treatment of X-Linked Agammaglobulinemia. Their top areas of expertise are Multisystem Inflammatory Syndrome in Children (MIS-C), X-Linked Agammaglobulinemia, Febrile Neutropenia, and Primary Immunodeficiency (PID).

Their clinical research consists of co-authoring 64 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of X-Linked Agammaglobulinemia.

Locations

Rotterdam, ZH, Netherlands
Other Locations
Zuideinde, OV, Netherlands
Groningen, GR, Netherlands
Leiden, ZH, Netherlands
Bilthoven, UT 3720AL, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients Aged 4 to 11 Years With Activated Phosphoinositide 3-Kinase Delta Syndrome Followed by an Open-label Long-term Extension
An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients Aged 4 to 11 Years With Activated Phosphoinositide 3-Kinase Delta Syndrome Followed by an Open-label Long-term Extension
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2025
Intervention Type: Drug
Study Phase: Phase 3

64 Total Publications

Immunity to Streptococcus pyogenes and Common Respiratory Viruses at Age 0 to 4 Years After COVID-19 Restrictions.
Immunity to Streptococcus pyogenes and Common Respiratory Viruses at Age 0 to 4 Years After COVID-19 Restrictions.
Journal: JAMA network open
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Vermont's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile